Cantor Fitzgerald started coverage on shares of GlycoMimetics (NASDAQ:GLYC – Free Report) in a research note published on ...

Allakos Inc. (NASDAQ:ALLK – Get Free Report) was the recipient of a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 1,940,000 ...

A research team has uncovered new insights into the molecular mechanisms of ADAR1, a protein that regulates ribonucleic acid (RNA) induced immune responses. Their findings could open new pathways for ...

Researchers uncover new insights into the molecular mechanisms of ADAR1, a protein that regulates RNA-induced immune ...

Scientists have made a major discovery about ADAR1—a protein that controls RNA-induced immune responses—paving ...

Welch Foundation, Cancer Prevention and Research Institute of Texas, NIH/National Institutes of Health ...

A research team led by Rice University's Yang Gao has uncovered new insights into the molecular mechanisms of ADAR1, a protein that regulates ...

Newly discovered ADAR1 inhibitor exhibits antitumor effects in prostate cancer March 7, 2025 Novel therapeutic targets for treating the disease remain an unmet need.

That financing will be led by Cormorant Asset Management and will see the likes of Novo Holdings, ADAR1 Capital Management, Omega Funds and BioCapital Advisors, to name a few, scooping up the stock.

ADAR1 is an important regulator of aging, knockdown of ADAR1 can lead to cellular senescence, and overexpression of ADAR1 can prevent senescence from occurring. In the present study, we constructed ...